N Therapeutics

N Therapeutics is a South Korean biotechnology company founded in 2019 by Professor Jae Seung Kang of the Seoul National University College of Medicine. The company specializes in developing advanced drug delivery systems to maximize therapeutic efficacy and minimize side effects for hard-to-treat diseases. Its core proprietary platforms include NanoSil, a porous silicon nanoparticle-based platform designed for targeted delivery such as crossing the blood-brain barrier for glioblastoma, and BioSil, a transdermal and mucosal delivery platform for chronic inflammatory skin conditions like psoriasis and atopic dermatitis. N Therapeutics is advancing a pipeline of therapeutics, including its lead candidate NS-001-TEM (temozolomide-loaded nanoparticles) for glioblastoma, as well as treatments for pancreatic cancer, respiratory viral infections, and inflammatory skin diseases.